Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00443352 · ClinicalTrials.gov registry record · Phase 4

A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache

A Phase 4 study, sponsored by Thomas Jefferson University.

Completed
Registry status
Phase 4
Development phase
27
Enrollment target

NCT00443352 is a Phase 4 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00443352, a Phase 4 study, has completed, sponsored by Thomas Jefferson University.

COMPLETED
Registry status
Phase 4
Development phase
27 participants
Enrollment target

Study Summary

This is a single-center, open-label, pilot trial to collect and evaluate data on the safety and efficacy of duloxetine in the preventive treatment of subjects experiencing episodic migraine headaches. Following a 28-day baseline period, qualifying subjects will be entered into an 84-day treatment period. Subjects will be titrated over the first four weeks to a dose of 120mg or their maximally tolerated dose (MTD). The dose adjustments will be based on individual subject response and/or subject's tolerability. Subjects will maintain a daily diary capturing detailed information on migraine headache days.

Interventions

  • DRUG duloxetine

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2007-08
Est. Completion 2012-11
Phase Phase 4

Sponsor

Thomas Jefferson University

292 total trials

What the Registry Record Tells You About NCT00443352

The ClinicalTrials.gov registry entry for NCT00443352 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which duloxetine is the first listed.

NCT00443352 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00443352 about?

NCT00443352 is a clinical study titled "A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache". This is a single-center, open-label, pilot trial to collect and evaluate data on the safety and efficacy of duloxetine in the preventive treatment of subjects experiencing episodic migraine headaches. Following a 28-day baseline period, qualifying subjects will be entered into an 84-day treatment pe...

What is the current status of trial NCT00443352?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2007-08. Estimated completion is 2012-11.

What interventions are being tested in trial NCT00443352?

The interventions under investigation include: duloxetine (DRUG).

Who is sponsoring clinical trial NCT00443352?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.